Navigation Links
Win a $10,000 Education Fund for Your Miracle Child
Date:4/9/2008

Ferring Pharmaceuticals Announces 2008 My Little Miracle Essay Contest

PARSIPPANY, N.J., April 9, 2008 /PRNewswire/ -- If you are a parent who has successfully given birth using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Eleven other education fund prizes will also be awarded. To be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are just beginning their journey to parenthood and how you would describe your success using BRAVELLE(R) (urofollitropin for injection, purified) and/or MENOPUR (R) (menotropins for injection, USP) as part of your treatment plan.

Ferring's My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE(R) and/or MENOPUR(R). The contest celebrates the miracle of birth for parents who have faced infertility, and carries on Ferring's tradition of supporting patients by offering education funds for the winners' children.

Ferring is also awarding a $2,500 education fund to the runner up and $500 each to 10 honorable mention winners. Since announcing the first contest in 2004, Ferring has awarded $85,000 in education funds.

Essays should not exceed 2,000 words. They must be written in English, include the entrant's name, address, phone number and age, as well as the child(ren)'s name(s) and age(s), and be submitted with a contest application and labeled digital photo. Entries must be postmarked by August 30, 2008. Winners will be announced at the 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM), November 8-12, 2008.

For more details and a contest application, visit http://www.ferringfertility.com or http://www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

BRAVELLE(R) and MENOPUR (R), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE(R) and/or MENOPUR (R) may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE(R), MENOPUR(R), REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R)/DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit http://www.ferringusa.com or http://www.ferringfertility.com.

Please contact Christine Stroup for full prescribing information.


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Eastern Ergonomics Conference, June 24 in New York City; New One-Day Format, Focus on Core Ergonomics Education
2. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
3. Ventria Receives Friends of Education Award From Geary County School District
4. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
5. The American Fertility Association Brings Fertility Education to San Francisco or Parent Hopefuls - Straight and Gay
6. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
7. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
8. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
9. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
10. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
11. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... ALBANY, New York , March 22, 2017 /PRNewswire/ ... market is largely fragmented, states a research report by ... Sanofi S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., ... market in 2015. The prominent players in this market ... to expand their product portfolio, which is likely to ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
Breaking Biology News(10 mins):